Ensysce Biosciences
LA JOLLA, California, United States · Banking, Biotechnology, Finance
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Key facts
- Headquarters
- LA JOLLA, California, United States
- Employees
- 12
- Industries
- Banking, Biotechnology, Finance
- Status
- Public (ENSC)
- Website
- ensysce.com
- Company page
Recent activity at Ensysce Biosciences
- : Leadership Transition at Ensysce Biosciences
- : Ensysce acquires Cy Biopharma for $77 million
- : SEC 8-K (5.02): On October 29, 2026, Dr. Lynn Kirkpatrick, the Chief Executive Officer of Ensysce Biosciences Inc., agreed to take on the role of Chief Operating Officer immediately after the Company's Annual Meeting scheduled for December 14, 2026. This change is linked to the resignation of Mr. Will Chang, a member of the Board of Directors, who plans to resign after the Annual Meeting. Dr. Kirkpatrick has confirmed that this title change will not trigger severance obligations according to her Executive Employment Agreement. The transition emphasizes a significant shift in leadership as Mr. James Morrisson is set to be appointed as the new Chief Executive Officer following the meeting, indicating a strategic realignment in the company's management structure.
- : SEC 8-K (8.01): On August 25, 2026, Ensysce Biosciences Inc. received notification from Nasdaq confirming that the company complies with the $2.5 million stockholders’ equity requirement under Rule 5550(b)(1). This followed a previous notice on May 21, 2026, regarding potential delisting due to non-compliance as of March 31, 2026. The company submitted a compliance plan within the required timeframe and believes it can demonstrate continued compliance in its next periodic report. Failure to do so will lead to a delisting from Nasdaq, impacting its ability to raise capital and trade publicly.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing of a Merger Agreement. Concurrently, James Morrison was appointed as President and Director. Mr. Morrison, who previously served as the President of Cy and has a strong background in developing therapies for neurological conditions, will also take on the role of Chief Executive Officer upon stockholder approval of the Meeting Proposals. There are no disclosed arrangements or family relations that could influence his appointment, ensuring a clean transition amidst the corporate changes.
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On April 6, 2026, Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 2,000 shares of Series B preferred stock, convertible into up to 4,363,636 shares of common stock, and warrants to purchase up to 8,727,273 shares of common stock, for gross proceeds of $2 million. In connection with this investment, the company amended the Certificate of Designation of the Series B Preferred Stock, increasing its stated value from $1,100 to $1,200. The warrants, which have an exercise price of $0.55, are subject to adjustment for anti-dilution provisions. This transaction enhances the company's capital structure and increases investor confidence.
- : SEC 8-K (5.02): On April 1, 2026, Ensysce Biosciences Inc. received a resignation notice from Curtis Rosebraugh, effective that same day. Dr. Rosebraugh was a member of the Board of Directors and had served on the Nominating and Corporate Governance Committee. His departure may impact the company's governance structure and committee operations, marking a significant change in the leadership of the board. The notice of resignation is attached as Exhibit 17 to this Form 8-K.
- : SEC 8-K (5.02): On March 24, 2026, Lee Rauch resigned from the Board of Directors of Ensysce Biosciences Inc., effective the same day. Ms. Rauch served on various committees including the Audit and Compensation Committees and opposed the proposed severance packages for key managers during a period where the company is considering strategic alternatives. The Board approved these severance packages on March 27, 2026, amounting to approximately $205,475, which include conditions for retention and claim releases in case of strategic transactions. This resignation and subsequent board decision are crucial for the company's ongoing management strategy during this transitional phase.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Ensysce Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2025 | Seed | $2.2M |
| Mar 2025 | Seed | $1.1M |
| Aug 2024 | Venture | $5.1M |
| Feb 2024 | Seed | $4.7M |
| Feb 2023 | Seed | $2.8M |
Leadership
- D Kirkpatrick, Executive Officer, Director
- Bob Gower, Director
- William Chang, Director
- Andrew Benton, Director
- Steve Martin, Director
- Adam Levin, Director
- Curtis Rosebraugh, Director
- James Morrisson, President
- Lynn Kirkpatrick, Chief Operating Officer
- Steve Klein, Director
- Paul Davis, Consultant, Fintechs
- Marty Arrivo, Executive Director
Verified email and direct lines for Ensysce Biosciences’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Ensysce Biosciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Ensysce Biosciences in the news
- Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Yahoo Finance (Jul 14, 2026)
- Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Yahoo Finance (Aug 06, 2026)
- Form PRE 14A Ensysce Biosciences For: 30 October By Investing.com - Investing.com Canada (Oct 30, 2026)
- What Changed at Ensysce Biosciences (NASDAQ:ENSC) After Its Cy Biopharma Acquisition? - Kalkine (Nov 13, 2026)
- Ensysce Biosciences (Nasdaq:ENSC) - Stock Analysis - Simply Wall St (Jul 06, 2021)
- Ensysce Biosciences (ENSC) Stock Price, News & Analysis - MarketBeat (Jul 06, 2021)
- Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why - Yahoo Finance (Apr 23, 2025)
- Ensysce Biosciences, Inc. (ENSC) stock price, news, quote and history - Yahoo Finance Australia (Aug 17, 2021)
Companies similar to Ensysce Biosciences
- USBC · Biotechnology, Finance, Financial Services, Fintech, Hardware, Lending, Manufacturing
- Hyperion Defi, Inc. · Finance, Financial Services, Fintech, Healthcare, Lending, Manufacturing
- Alkami Technology · Banking, Finance, Financial Services, Fintech, Hardware, Lending
- Andersen Corporation · Banking, Finance, Financial Services, Fintech, Lending, Manufacturing
- Charter Communications · Banking, Biotechnology, Finance, Financial Services, Hardware, Lending
About Ensysce Biosciences: questions and answers
What does Ensysce Biosciences do?
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Where is Ensysce Biosciences headquartered?
Ensysce Biosciences is headquartered in LA JOLLA, California, United States.
How many employees does Ensysce Biosciences have?
Ensysce Biosciences has about 12 employees.
Has Ensysce Biosciences raised funding?
Yes. Fundz has recorded 5 funding events for Ensysce Biosciences. The most recent, Seed of $2.2M, was in Apr 2025.
Who leads Ensysce Biosciences?
James Morrisson is a President at Ensysce Biosciences.
What is the latest news on Ensysce Biosciences?
On Nov 4, 2026, Leadership Transition at Ensysce Biosciences
Is Ensysce Biosciences a public company?
Yes. Ensysce Biosciences is publicly traded under the ticker ENSC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy